Unit of Mycobacteriology/UPMM, Institute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa, Lisbon, Portugal.
Int J Antimicrob Agents. 2010 Jun;35(6):524-6. doi: 10.1016/j.ijantimicag.2009.12.019. Epub 2010 Feb 25.
Thioridazine (TDZ) has been shown to have in vitro activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, to promote the killing of intracellular MDR and XDR strains and to cure the mouse of antibiotic-susceptible and -resistant pulmonary tuberculosis (TB) infections. Recently, TDZ was used to cure 10 of 12 XDR-TB patients in Buenos Aires, Argentina. At the time of writing, it is being used for the therapy of non-antibiotic-responsive terminal XDR-TB patients in Mumbai, India, on the basis of compassionate therapy and although it is too early to determine a cure, the patients have improved appetite, weight gain, are afebrile and free of night sweats, and their radiological picture shows great improvement. Because XDR-TB is essentially a terminal disease in many areas of the world and no new effective agents have yet to yield successful clinical trials, global clinical trials for the therapy of XDR-TB are urgently required.
硫利达嗪（TDZ）已被证明具有体外抗多药耐药（MDR）和广泛耐药（XDR）结核分枝杆菌菌株的活性，可促进杀死细胞内 MDR 和 XDR 菌株，并治愈对抗生素敏感和耐药的肺结核（TB）感染的小鼠。最近，TDZ 被用于治愈阿根廷布宜诺斯艾利斯的 12 名 XDR-TB 患者中的 10 名。在撰写本文时，它正在印度孟买根据同情治疗用于治疗没有抗生素反应的晚期 XDR-TB 患者，尽管确定治愈还为时过早，但患者的食欲、体重增加、不发热且无夜间盗汗，其影像学显示出很大的改善。由于 XDR-TB 在世界许多地区基本上是一种终末期疾病，而且尚无新的有效药物已成功进行临床试验，因此迫切需要进行全球 XDR-TB 治疗的临床试验。
